ABC 294640

Drug Profile

ABC 294640

Alternative Names: ABC-294640; YELIVA

Latest Information Update: 29 Dec 2016

Price : $50

At a glance

  • Originator Apogee Biotechnology Corporation
  • Developer Apogee Biotechnology Corporation; Medical University of South Carolina; RedHill Biopharma
  • Class Antineoplastics; Small molecules
  • Mechanism of Action Sphingosine kinase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity Yes
  • Available For Licensing Yes - Cancer; Inflammation

Highest Development Phases

  • Phase II Hepatocellular carcinoma
  • Phase I/II Diffuse large B cell lymphoma; Multiple myeloma
  • Phase I Solid tumours
  • Preclinical Cholangiocarcinoma; Inflammatory bowel diseases; Osteoarthritis; Prostate cancer; Radiation injuries; Rheumatoid arthritis

Most Recent Events

  • 29 Nov 2016 Pharmacodynamics data from preclinical trials in Solid tumours at the 28th EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics (EORTC-NCI-AACR-2016)
  • 21 Nov 2016 ABC 294640 is available for licensing as of 21 Nov 2016. www.redhillbio.com
  • 05 Oct 2016 Phase-II clinical trials in Hepatocellular carcinoma (Second-line therapy or greater, Late-stage disease) in USA (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top